A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration

被引:27
|
作者
Sime, Fekade B. [1 ,2 ]
Lassig-Smith, Melissa [3 ]
Starr, Therese [3 ]
Stuart, Janine [3 ]
Pandey, Saurabh [1 ]
Parker, Suzanne L. [1 ]
Wallis, Steven C. [1 ]
Lipman, Jeffrey [1 ,3 ,4 ]
Roberts, Jason A. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Queensland, Ctr Clin Res, Fac Med, Brisbane, Qld, Australia
[2] Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Sch Pharm, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[4] Univ Montpellier, Nimes Univ Hosp, Div Anaesthesiol Crit Care Emergency & Pain Med, Nimes, France
[5] Royal Brisbane & Womens Hosp, Pharm Dept, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
ceftolozane-tazobactam; pharmacokinetics; renal replacement therapy; hemodiafiltration; CRRT; RENAL REPLACEMENT THERAPY; PSEUDOMONAS-AERUGINOSA; CLEARANCE;
D O I
10.1128/AAC.01655-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aim of this work was to describe optimized dosing regimens of ceftolozane-tazobactam for critically ill patients receiving continuous venovenous hemodiafiltration (CVVHDF). We conducted a prospective observational pharmacokinetic study in adult critically ill patients with clinical indications for ceftolozane-tazobactam and CVVHDF. Unbound drug concentrations were measured from serial prefilter blood, postfilter blood, and ultrafiltrate samples by a chromatographic assay. Population pharmacokinetic modeling and dosing simulations were performed using Pmetrics. A four-compartment pharmacokinetic model adequately described the data from six patients. The mean (+/- standard deviation [SD]) extraction ratios for ceftolozane and tazobactam were 0.76 +/- 0.08 and 0.73 +/- 0.1, respectively. The mean +/- SD sieving coefficients were 0.94 +/- 0.24 and 1.08 +/- 0.30, respectively. Model-estimated CVVHDF clearance rates were 2.7 +/- 0.8 and 3.0 +/- 0.6 liters/h, respectively. Residual non-CVVHDF clearance rates were 0.6 +/- 0.5 and 3.3 +/- 0.9 liters/h, respectively. In the initial 24 h, doses as low as 0.75 g every 8 h enabled cumulative fractional response of >= 85% for empirical coverage against Pseudomonas aeruginosa, considering a 40% fT (>MIC) (percentage of time the free drug concentration was above the MIC) target. For 100% fT (>MIC), doses of at least 1.5 g every 8 h were required. The median (interquartile range) steady-state trough ceftolozane concentrations for simulated regimens of 1.5 g and 3.0 g every 8 h were 28 (21 to 42) and 56 (42 to 84) mg/liter, respectively. The corresponding tazobactam concentrations were 6.1 (5.5 to 6.7) and 12.1 (11.0 to 13.4) mg/liter, respectively. We suggest a front-loaded regimen with a single 3.0-g loading dose followed by 0.75 g every 8 h for critically ill patients undergoing CVVHDF with study blood and dialysate flow rates.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis
    Selig, Daniel J.
    DeLuca, Jesse P.
    Chung, Kevin K.
    Pruskowski, Kaitlin A.
    Livezey, Jeffrey R.
    Nadeau, Robert J.
    Por, Elaine D.
    Akers, Kevin S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (08) : 1091 - 1102
  • [32] Factors affecting serum concentration of vancomycin in critically ill oliguric pediatric patients receiving continuous venovenous hemodiafiltration
    Lee, Bongjin
    Kim, Soo Jung
    Park, June Dong
    Park, Jiun
    Jung, Ae Hee
    Jung, Sun Hoi
    Choi, Yu Hyeon
    Kang, Hee Gyung
    Ha, Il Soo
    Cheong, Hae Il
    PLOS ONE, 2018, 13 (06):
  • [33] Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration
    Varghese, Julie M.
    Jarrett, Paul
    Boots, Robert J.
    Kirkpatrick, Carl M. J.
    Lipman, Jeffrey
    Roberts, Jason A.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (04) : 343 - 348
  • [34] Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration
    Ververs, TFT
    van Dijk, A
    Vinks, SATMM
    Blankestijn, PJ
    Savelkoul, TJF
    Meulenbelt, J
    Boereboom, FTJ
    CRITICAL CARE MEDICINE, 2000, 28 (10) : 3412 - 3416
  • [35] Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model
    Minichmayr, Iris K.
    Roberts, Jason A.
    Frey, Otto R.
    Roehr, Anka C.
    Kloft, Charlotte
    Brinkmann, Alexander
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (05) : 1330 - 1339
  • [36] Pharmacokinetic optimization of dosing regimen of aminosides and vancomycin in critically ill patients receiving continuous renal replacement
    Yamamoto, T.
    Yasuno, N.
    Hisaka, A.
    Katada, S.
    Hanafusa, N.
    Suzuki, H.
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 511 - 511
  • [37] Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration
    Bilgrami, I.
    Roberts, J. A.
    Wallis, S. C.
    Thomas, J.
    Davis, J.
    Fowler, S.
    Goldrick, P. B.
    Lipman, J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (07) : 2974 - 2978
  • [38] A prospective, real-world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADRE-02)
    Kalaria, Shamir N.
    Armahizer, Michael
    McCarthy, Paul
    Badjatia, Neeraj
    Gobburu, Jogarao, V
    Gopalakrishnan, Mathangi
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (11) : 4375 - 4385
  • [39] Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration
    Chuk, Amanda C.
    Saeed, Fahad
    Kousar, Nadia
    Burrill, Susan
    Barns, Barry
    Rickrode, Geoffrey
    Fu, Jacqueline
    Katrych, Oleksandra
    Saunders-Hao, Patricia
    Block, Clay
    Lahey, Tim
    CLINICAL NEPHROLOGY, 2015, 84 (04) : 214 - 221
  • [40] Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration
    Perez-Pitarch, Alejandro
    Ferriols-Lisart, Rafael
    Aguilar, Gerardo
    Ezquer-Garin, Carlos
    Belda, F. Javier
    Guglieri-Lopez, Beatriz
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 51 (01) : 115 - 121